The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA Reports
Abstract
OBJECTIVE: Previous reports suggesting that selective serotonin reuptake inhibitor (SSRI) use is associated with increased suicidal risk have not assessed completed suicides. The authors analyzed reports from randomized controlled trials to compare suicide rates among depressed patients assigned to an SSRI, other antidepressants, or placebo. METHOD: Food and Drug Administration (FDA) summary reports of the controlled clinical trials for nine modern FDA-approved antidepressants provided data for comparing rates of suicide. RESULTS: Of 48,277 depressed patients participating in the trials, 77 committed suicide. Based on patient exposure years, similar suicide rates were seen among those randomly assigned to an SSRI (0.59%, 95% confidence interval [CI]=0.31%-0.87%), a standard comparison antidepressant (0.76%, 95% CI=0.49%-1.03%), or placebo (0.45%, 95% CI=0.01%-0.89%). CONCLUSIONS: These findings fail to support either an overall difference in suicide risk between antidepressant- and placebo-treated depressed subjects in controlled trials or a difference between SSRIs and either other types of antidepressants or placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Emergence of intense suicidal preoccupation during fluoxetine treatment
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.207 · Cited by 532
Khan, A., Warner, H. A., & Brown, W. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.4.311 · Cited by 477
Self-citationFluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley, C. M., Dornseif, B. E., Bosomworth, J. C., Sayler, M. E., Rampey, A. H., Heiligenstein, J. H., Thompson, V. L., Murphy, D. J., & Masica, D. N. (1991) · BMJ · doi:10.1136/bmj.303.6804.685 · Cited by 361
Khan, A., Khan, S. R., Leventhal, R. M., & Brown, W. A. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002322 · Cited by 98
Self-citationSuicide in the course of the treatment of depression
Healy, D. T., Langmaack, C., & Savage, M. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300110 · Cited by 65
Emergence of antidepressant induced suicidality
Healy, D. (2000) · Primary Care and Community Psychiatry · doi:10.1185/135525700543163 · Cited by 51
Functional effects of agents differentially selective to noradrenergic or serotonergic systems
Tranter, R., HEALY, H., Cattell, D., & HEALY, D. (2002) · Psychological Medicine · doi:10.1017/s0033291701005086 · Cited by 20
Cited by
Suicide Prevention Strategies: A Systematic Review
Mann, J. J., Apter, A., Bertolote, J., Beautrais, A., Currier, D., Haas, A., Hegerl, U., Lonnqvist, J., Malone, K., Marusic, A., et al. (2005) · JAMA · doi:10.1001/jama.294.16.2064 · Cited by 2,852
The psychology of suicidal behaviour
O'Connor, R. C., & Nock, M. K. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70222-6 · Cited by 1,193
Kessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Decreased risk of suicides and attempts during long‐term lithium treatment: a meta‐analytic review
Baldessarini, R. J., Tondo, L., Davis, P., Pompili, M., Goodwin, F. K., & Hennen, J. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00344.x · Cited by 753
Metadata
- Authors
- Khan, A., Khan, S., Kolts, R., & Brown, W. A.
- Venue
- American Journal of Psychiatry
- Published
- 2003-04-01
- Volume
- 160
- Issue
- 4
- Pages
- 790-792
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2139776066
- Cited by
- 394
- References
- 8
- FWCI
- 52.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.